Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab

Paolo Ghiaa Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, ItalyCorrespondence[email protected]

Gisoo Barnesb Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA

Keri Yangb Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA

Constantine S. Tamc The Alfred Hospital, Melbourne, VIC, Australia;d Monash University, Clayton, VIC, Australia

Tadeusz Robake Department of Hematology, Medical University of Lodz, Lodz, Poland

Jennifer R. Brownf Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

https://orcid.org/0000-0003-2040-4961

Brad S. Kahlg Department of Medicine, Washington University School of Medicine, St Louis, MO, USA

Tian Tianb Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA

Andy Szetob Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA

Jason C. Paikb Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA

Mazyar Shadmanh Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA;i Department of Medicine, University of Washington, Seattle, WA, USA

show all

Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab

Spp Table 2 304.docx

Spp Table 1 304.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab

Spp Table 2 304.docx

Spp Table 1 304.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date